Their findings revealed that these AXL-targeted agents exhibited dose-dependent cytotoxicity in both FLT3-mutant AML cell lines (MV4-11 and quizartinib-resistant MV4-11) and primary AML blast cells from FLT3-ITD+ patients, especially when combined with quizartinib. This evidence concerns the gene AXL and acute myeloid leukemia.